Click here for slides on this topic


Free fatty acid (FFA)

The fraction of plasma fatty acids that is not in esterified form of glycerol esters. Also know as non-esterified fatty acids.
The following content matched the glossary term: Free fatty acid (FFA)

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes

Top

Kashyap SR, Bhatt DL, Wolski, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175-2182.

NDEI.org Press Release Vivian Fonseca, MD, on “Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit” in the ORIGIN Trial

Top

Vivian Fonseca, MD, on the "Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit" in the ORIGIN Trial July 31, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today a webcast on the results of the ORIGIN trial featuring expert commentary from Vivian A. Fonseca, MD. “These results may help us to education our patients on the futility of adding omega-3 fatty acids in the hope of added benefit, in the absence of data supporting their use,” said Dr Fonseca, a Professor of Medicine and Pharmacology, and Chief of the Section of Endocrinology at Tulane University Health Sciences Center in New Orleans, Louisiana.

Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population

Top

Shigetoh Y, Adachi H, Yamagishi S, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertension.. 2009;22(2):151-155. Emerging evidence indicates an association between sympathetic activation and metabolic syndrome. However, sympathetic activation in metabolic syndrome may be a cause, consequence, or just epiphenomenon.

Relationship between changes in insulin sensitivity & associated CVD risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals

Top

Abbasi F, Lima NK, Reaven GM. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism. 2009;58(3):373-378. This study compared the effects of administering rosiglitazone (RSG) vs pioglitazone (PIO) on cardiovascular disease risk factors in insulin-resistant, nondiabetic individuals with no apparent disease.

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in yype 2 diabetic patients

Top

Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2008 Dec 16. [Epub ahead of print]. Dipeptidyl-peptidase-IV (DPP-4) inhibition increases endogenous GLP-1 activity resulting in improved glycemic control in patients with type 2 diabetes mellitus.

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects

Top

Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007 Aug;30(8):1945-51. Epub 2007 May 4. OBJECTIVE: The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome.

Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention

Top

Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes. 2007;56:248-255. Elevated plasma free fatty acid (FFA) levels are responsible for much of the insulin resistance in obese patients with type 2 diabetes.

Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization

Top

Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab. 2006;91:3553-3558. We have previously demonstrated an early and potent antiinflammatory effect of troglitazone and rosiglitazone.

1 2 3 Next 

Slide Library Results

Search Results for: Free fatty acid (FFA) Slides Found: 0